Diagnostics Biochem Canada (DBC) is a pioneering company founded in 1973, with a mission to develop and market unique immunoassay kits that significantly impact the field of diagnostics and public health. Operating within the industries of Biotechnology, Health Care, and Manufacturing, DBC's commitment to quality and innovation has positioned them as a leading manufacturer of high-quality immunoassays in the global market.
With a headquarter in Canada, DBC constantly seeks out new technologies and applications that have the potential to enhance disease diagnosis, ultimately improving the quality of life for people worldwide. While the details of their last investment and investors are not yet disclosed, DBC's unwavering dedication to advancing diagnostic solutions makes them an intriguing prospect for venture capital firms seeking to invest in cutting-edge healthcare technology startups.
There is no investment information
No recent news or press coverage available for Diagnostics Biochem Canada (DBC).